GSK PLC Sponsored ADR (NYSE:GSK) Stock Has Average Price Target of $56.50

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have been given a consensus rating of “Hold” by the eleven research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $56.50.

Several research analysts have commented on the stock. Morgan Stanley reissued an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a report on Thursday, July 30th. Jefferies Financial Group upgraded shares of GSK to a “strong-buy” rating in a research report on Friday, July 17th. Citigroup initiated coverage on shares of GSK in a research note on Friday, July 24th. They issued a “neutral” rating for the company. Finally, Wall Street Zen lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st.

GSK Price Performance

GSK opened at $49.29 on Friday. The stock has a 50-day moving average price of $50.85 and a 200-day moving average price of $52.25. GSK has a 12-month low of $39.46 and a 12-month high of $61.69. The company has a current ratio of 0.82, a quick ratio of 0.52 and a debt-to-equity ratio of 0.81. The stock has a market capitalization of $99.71 billion, a P/E ratio of 15.41, a PEG ratio of 2.06 and a beta of 0.35.

GSK (NYSE:GSK) last announced its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.09. The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%.GSK’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Equities analysts predict that GSK will post 4.81 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Friday, August 14th will be paid a $0.4515 dividend. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.81 dividend on an annualized basis and a dividend yield of 3.7%. GSK’s dividend payout ratio is presently 55.63%.

Institutional Investors Weigh In On GSK

Several institutional investors have recently bought and sold shares of GSK. QRG Capital Management Inc. increased its stake in GSK by 7.6% in the 2nd quarter. QRG Capital Management Inc. now owns 191,512 shares of the pharmaceutical company’s stock worth $10,039,000 after purchasing an additional 13,519 shares during the period. Envestnet Portfolio Solutions Inc. boosted its stake in shares of GSK by 3.3% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 18,135 shares of the pharmaceutical company’s stock valued at $951,000 after purchasing an additional 585 shares during the period. Security National Bank of SO Dak purchased a new stake in shares of GSK during the second quarter valued at approximately $38,000. Keystone Financial Planning Inc. grew its holdings in shares of GSK by 3,114.8% in the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock worth $10,253,000 after purchasing an additional 189,506 shares during the last quarter. Finally, Sequoia Financial Advisors LLC increased its stake in shares of GSK by 1.8% in the second quarter. Sequoia Financial Advisors LLC now owns 36,293 shares of the pharmaceutical company’s stock worth $1,902,000 after buying an additional 641 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

About GSK

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.